Compare SA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SA | NUVB |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | Canada | United States |
| Employees | N/A | 291 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 1.6B |
| IPO Year | 2004 | N/A |
| Metric | SA | NUVB |
|---|---|---|
| Price | $33.83 | $4.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $65.00 | $11.22 |
| AVG Volume (30 Days) | 769.3K | ★ 4.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $182.76 |
| Revenue Next Year | N/A | $91.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $1.57 |
| 52 Week High | $40.06 | $9.75 |
| Indicator | SA | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 35.41 |
| Support Level | $28.46 | $4.04 |
| Resistance Level | $40.06 | $5.73 |
| Average True Range (ATR) | 1.83 | 0.33 |
| MACD | -0.43 | -0.04 |
| Stochastic Oscillator | 25.68 | 24.78 |
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.